Search Results (1 to 1 of 1 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 1 JMIR Formative Research
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Research Protocols
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
The overall survival time ranged from 181 to 1379 days (median 1051). Although all 3 had advanced-stage disease and received similar treatment with rituximab and bendamustine, one patient with a baseline SUVmax of 5.2 died without achieving complete metabolic remission, reflecting no meaningful correlation between SUVmax and survival in this limited number of patients.
Currently, there is no consensus on the optimal discriminatory baseline SUVmax for indolent lymphomas.
JMIR Form Res 2021;5(11):e24936
Download Citation: END BibTex RIS